Mira Pharmaceuticals(MIRA.US)

Last Updated 19:00:00 ET
longbridge loading

Mira Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0

Earnings Watch·
US
MIRA
+1.85%
Earnings Watch·
US
MIRA
+1.85%

MIRA Pharmaceuticals Reports Positive Phase 1 Ketamir-2 Results

Tip Ranks·
US
MIRA
+1.85%
US
IHE
+0.84%
US
IBB
+2.27%
Tip Ranks·
US
MIRA
+1.85%
US
IHE
+0.84%
US
IBB
+2.27%

MIRA highlights SKNY-1 preclinical data in new publication

Tip Ranks·
US
MIRA
+1.85%
US
IXJ
+0.35%
US
BBH
+0.96%
Tip Ranks·
US
MIRA
+1.85%
US
IXJ
+0.35%
US
BBH
+0.96%

15:50 ETmiraDry® Reports 55% Growth in Patient Spend, Significantly Outpacing Aesthetic Energy-Based Device Market, and Kicks Off Odor Awareness Week

prnewswire·
DE
GME
0.00%
SH
CS精准医
+0.59%
US
MIRA
+1.85%
prnewswire·
DE
GME
0.00%
SH
CS精准医
+0.59%
US
MIRA
+1.85%

Mira Pharmaceuticals | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
MIRA
+1.85%
Earnings Watch·
US
MIRA
+1.85%

Mira Pharmaceuticals 10-K: $— Revenue, $(1.35) EPS, $(10.44) M Net Loss

TradingView·
US
BBH
+0.96%
US
PBE
+1.60%
US
MIRA
+1.85%
TradingView·
US
BBH
+0.96%
US
PBE
+1.60%
US
MIRA
+1.85%

What's Going On With MIRA Pharma Stock Tuesday?

benzinga_article·
US
FBT
+2.14%
US
XBI
+3.88%
US
SBIO
+3.75%
benzinga_article·
US
FBT
+2.14%
US
XBI
+3.88%
US
SBIO
+3.75%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga_article·
US
XLV
-0.13%
US
IBB
+2.27%
US
LABU
+11.76%
benzinga_article·
US
XLV
-0.13%
US
IBB
+2.27%
US
LABU
+11.76%

MIRA Pharmaceuticals shares are trading higher after the company announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated behavioral assays.

benzinga_article·
US
LABU
+11.76%
US
BBH
+0.96%
US
IBB
+2.27%
benzinga_article·
US
LABU
+11.76%
US
BBH
+0.96%
US
IBB
+2.27%
© 2026 Longbridge｜Disclaimer